Download PDF – TiNivo-2 FOTIVDA® (tivozanib) monotherapy (control arm) results provide clinically meaningful efficacy and safety data following front-line immune checkpoint inhibitor (ICI) combinations – – TIVO-3 Exploratory Overall Survival (OS) Analysis Provides Additional Data for FOTIVDA Following Immunotherapy – – Safety results support the well-established safety profile of FOTIVDA – BOSTON, September 16, 2024
Download PDF BOSTON, September 3, 2024 (PR Newswire) – AVEO Oncology, an LG Chem company (“AVEO”), announced today their late-breaking abstract detailing their Phase 3 TiNivo-2 trial has been selected as a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain this September 13-17th. The oral presentation
Download PDF – The addition of nivolumab to low dose tivozanib after prior immune checkpoint inhibitor (ICI) is not superior to standard dose tivozanib alone; as a result, the primary endpoint was not met – – Tivozanib monotherapy (control arm) results provide clinically meaningful efficacy and safety data following front-line ICI combinations – – Safety
Download PDF – LG Chem to embark on developing Next-Generation Immune Checkpoint Inhibitors to Provide Solid Tumor Treatment Solutions – – LG Chem and AVEO Oncology continuing to advance its shared vision of becoming a leading global oncology company – BOSTON, June 13, 2024 (PR Newswire) — LG Chem and AVEO Oncology, an LG Chem
Download PDF – Industry veteran brings extensive clinical development experience to AVEO Oncology leadershipteam as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned cancer institutions – BOSTON, March 28, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline on March 25 by AVEO Pharmaceuticals, the text in
Download PDF BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) — AVEO Oncology, an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® (tivozanib) in patients with relapsed or refractory (R/R) advanced renal cell carcinoma
Download PDF BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) — AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with human papillomavirus (HPV)-negative recurrent or
Download PDF Boston, MA (November 30, 2023) — For the second year in a row, AVEO Oncology, an LG Chem company, has earned a spot on the Boston Globe’s annual ‘Top Places to Work in Massachusetts’ list. AVEO Oncology appears in the medium-sized company (100-249 employees) category. “We are incredibly excited to be selected once
For media inquiries, please contact:
John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352
The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.